Objective. To investigate the tolerability and impact on quality of life of liposomal
nasal spray compared to guideline-recommended
steroid-based
therapy in patients with chronic
rhinosinusitis. Symptom reduction and use of antisymptomatic medication were also examined. Methods. In this monocenter, prospective, controlled, open, and noninterventional study, 60 patients with chronic
rhinosinusitis were treated with liposomal
nasal spray and 30 patients received
steroid-based
therapy. The study comprised five visits occurring at intervals of two to four weeks. Efficacy was determined according to the
sinusitis symptom score documented daily. The
polyp score was recorded at the initial and final visits. Tolerability was determined through the
Nasal Spray Evaluation Questionnaire, and quality of life was ascertained with the SNOT-20 Score. Results. Both treatments achieved a significant reduction of
sinusitis symptoms (P < 0.05) and also rhinoscopic improvement (P < 0.05). The majority of patients assessed the treatments as "good" or "very good," and the quality of life improved significantly (P < 0.05). There was no significant difference in symptom reduction, QoL, and endoscopic exams between both treatments. Conclusion. The treatment of chronic
rhinosinusitis with liposomal
nasal spray results in a similar, significant reduction of symptoms and significant improvement in quality of life as guideline-recommended treatment and is therefore a comparable alternative.